Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Galvanizing bioelectronics

How Galvani plans to push forward on all fronts in bioelectronics

August 8, 2016 7:00 AM UTC

With disease biology expertise from GlaxoSmithKline plc and device development know-how from Verily Life Sciences LLC, newco Galvani Bioelectronics Ltd. plans to bring a commercial-grade bioelectronic therapeutic device to the clinic in about four years.

GSK and Verily formed Galvani last week. Each side will contribute IP, and together will provide up to £540 million ($713.9 million) in funding over seven years. GSK will own 55% of Galvani and Verily, formerly Google Life Sciences, will own the balance. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article